Vonoprazan
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Vonoprazan, sold under the brand name Voquezna among others, is a first-in-class potassium-competitive acid blocker medication.[2][1] Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.[2]
| |
| Clinical data | |
|---|---|
| Trade names | Voquezna, others |
| AHFS/Drugs.com | Voquezna |
| MedlinePlus | a624006 |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Potassium-competitive acid blocker |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Unknown |
| Protein binding | 80% |
| Metabolism | Liver, by cytochrome P450 (3A4, 2B6, 2C19, 2D6) |
| Elimination half-life | 7.7 h |
| Duration of action | > 24 h |
| Excretion | Kidney |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEBI | |
| ChEMBL |
|
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H16FN3O2S |
| Molar mass | 345.39 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
It was approved in Japan in February 2015,[3][4] and in Russia in April 2021.[5] Vonoprazan was approved for medical use in the United States in November 2023.[1][6] Co-packaged combinations of vonoprazan with amoxicillin and vonoprazan with amoxicillin and clarithromycin are available.[7][8]
Medical uses
Vonoprazan is indicated for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults; to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults; in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection in adults; in combination with amoxicillin for the treatment of H. pylori infection in adults.[1][7][9]
In July 2024, the indication was expanded in the US to include non-erosive gastroesophageal reflux disease.[10]
Adverse effects
The most common side effects are constipation, diarrhea, enlarged feeling of abdomen, nausea, rash, and edema.[1][11]
Long-term use may lead to vitamin B12 deficiency, hypomagnesemia, and fundic gland polyps.[11]
Society and culture
Names
Vonoprazan is the international nonproprietary name (INN).[12]
